Recombinant human thrombopoietin - 3SBio

Drug Profile

Recombinant human thrombopoietin - 3SBio

Alternative Names: rHuTPO - 3SBio; Tpiao

Latest Information Update: 09 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator 3SBio
  • Class Antianaemics; Colony-stimulating factors; Glycoproteins; Hepatoprotectants
  • Mechanism of Action Thrombopoietin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Idiopathic thrombocytopenic purpura; Thrombocytopenia
  • Preclinical Aplastic anaemia

Most Recent Events

  • 28 Jun 2018 Shenyang Sunshine Pharmaceutical initiates enrolment in a phase I trial for Thrombocytopenia in China (NCT03673215)
  • 28 Aug 2017 Phase-I clinical trials in Thrombocytopenia in China (SC) before August 2017 (3S Bio pipeline, December 2017)
  • 28 Aug 2017 Preclinical trials in Idiopathic thrombocytopenic purpura (In children, In infants, In neonates) in China (SC) before August 2017 (3S Bio pipeline, December 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top